Efficacy of Solifenacin and Tamsulosin for Treatment of Men with Lower Urinary Tract Symptoms and Overactive Bladder

Objective To assess the efficacy and safety of solifenacin and tamsulosin for the treatment of benign prostatic hyperplasia(BPH) patients with lower urinary tract symptoms(LUTS) and overactive bladder(OAB) . Methods Fifty BPH patients with OAB symptoms were treated with solifenacin 5 mg and tamsulosin 0.2 mg once daily for 4 weeks. A self-controlled clinical trial was conducted. The effectiveness and safety of the drug were observed by comparing the International Prostate Symptom Scores(IPSS) ,quality of life indexes(QOL) ,maximum urinary flow rates(Qmax) ,average urinary flow rates(Qave) ,voiding volumes(VV) ,daily micturition frequency,daily frequency of urgency incontinence,urgency and nocturia obtained before and after the treatment. Results After 4 weeks medication,46 assessable cases showed an average decrease of 9.25 in IPSS(P 0.01) ,3.37 in voiding symptom score(P 0.01) ,5.58 in urinary storage symptom score(P 0.01) and 2.45 in QOL(P 0.01) ,and a significant increase in Qmax、Qave and VV. Only 4.35% patients experienced the adverse event. Conclusion Combining solifenacin and tamsulosin is both effective and safe in the treatment of BPH patients with LUTS and OAB.